Neuland Laboratories Limited (NEULANDLAB) Fair Value & Analysis
Healthcare · IN · Market cap ₹244B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +11.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹11,555 – ₹18,988 · fair‑value band ₹4,191 – ₹7,802 · the ₹18,944 price screens above the ₹5,987 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Neuland Laboratories Limited (NEULANDLAB) currently trades at ₹18,944, while our model-based Fair Value estimate is ₹5,987 — implying the stock looks roughly 68.4% overvalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Neuland Laboratories Limited generated revenue of ₹6.1B at a net margin of 2.3%. Revenue grew 136.4% year over year. It earns a return on equity of 15.9%. The balance sheet holds a net cash position of ₹537M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Neuland Laboratories Limited reported revenue of ₹20.2B in FY2026 versus ₹9.2B in FY2022, a compound +21.7%/yr. Reported net income was ₹3.6B in FY2026, compounding +54.5%/yr from FY2022.
Is NEULANDLAB fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Neuland Laboratories Limited (NEULANDLAB) undervalued?
What is the fair value of NEULANDLAB?
What is the quality score of NEULANDLAB?
What is the revenue of Neuland Laboratories Limited (NEULANDLAB)?
What is the net profit margin of NEULANDLAB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.